ArticleCureus2026
Restage Transurethral Resection in the Evaluation of T1 High-Grade Bladder Tumor.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA considerable proportion of patients with T1 high-grade non-muscle invasive bladder cancer (NMIBC) advance to muscle-invasive disease, and the disease has a high rate of recurrence. Numerous approaches have been proposed in the literature to mitigate the consequences of the initial transurethral resection of bladder tumors (TURBT). We aimed to evaluate the T1 high-grade bladder tumor by restaging transurethral resection.
methodsThis was a descriptive observational study conducted in the Department of Urology, Sylhet MAG Osmani Medical College Hospital, Sylhet, from August 2023 to March 2024. A total of 41 patients with T1 high-grade urinary bladder tumors with the presence of a muscle layer in histopathology specimens were included in this study. Their demographic details, prior cystoscopy results, and histopathology reports were documented. A restaging TURBT was performed 2-6 weeks after the initial TURBT to reassess the T1 high-grade bladder tumor, focusing on the detection of any residual pathology.
resultsThe study included 41 patients, mostly male (92.7%), with a mean age of 64.6 ± 6.6 years. After restaging, 41.5% (17 patients) had no residual tumor, while 58.5% (24 patients) had residual tumor. Of those with residual tumor, 20 (48.8%) remained T1, and 4 (9.8%) were upstaged to T2. The majority had high-grade tumors (51.2%, 21 patients). Residual tumor was associated with a higher incidence of tumor size >3 cm (16.0% vs. 6.3%) and multiple tumors (16.0% vs. 0.0%).
conclusionRestaging transurethral resection of a T1 high-grade bladder tumor detects residual tumor and upstaging of disease, which remains crucial for staging purposes and subsequent therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.